TAG condemns the White House’s proposed retroactive $600 million cuts to CDC programs in four states. Because Congress already appropriated these funds, the cuts are illegal and unconstitutional, threatening HIV and public health programs nationwide. Congress must reject these partisan attacks and protect public health funding.
This National Black HIV/AIDS Awareness Day, Act Now: End AIDS and TAG uplift the truth: Black people are disproportionately impacted by HIV, and equity-driven solutions are essential. Ending the HIV epidemic requires confronting racism, expanding access to prevention and care, and ensuring that Black communities are centered, visible, and supported in public health efforts.
TAGLine 2025 documents a year of action as Treatment Action Group defended science, confronted attacks on public health, and fought to protect communities impacted by HIV, TB, and HCV.
Treatment Action Group (TAG) welcomes the news that the long-acting injectable HIV capsid inhibitor lenacapavir has proven efficacious at preventing HIV acquisition among young women and adolescent girls in South Africa and Uganda.
For Us By Us: PrEP in Black America, A Master Plan for HIV Prevention in Black America is a collaborative project from the PrEP in Black America coalition, which includes Treatment Action Group, PrEP4All, AVAC, Atlanta Black Women Leaders on PrEP, Equity & Impact Solutions, iStrive, Positive Impact Health Centers, and Red Hot.
To mark National Black HIV/AIDS Awareness Day on February 7, Treatment Action Group (TAG) is co-hosting a webinar “The Power of PrEP” in coalition with PrEP4All, Atlanta Black Women, AVAC, and iStrive.
Long-acting pre-exposure prophylaxis (PrEP) will be a groundbreaking HIV prevention tool. The approach provides an option to receive intermittent doses of PrEP instead of taking daily pills. This handout provides an update on the development of long-acting PrEP and future…
Treatment Action Group welcomes the announcement that the phase 3 HPTN 084 trial proved that intramuscular injections of ViiV’s long acting cabotegravir (CAB-LA) every eight weeks were superior to daily oral TDF/FTC pre-exposure prophylaxis (PrEP) in preventing new HIV infections in cisgender women in sub-Saharan Africa.
This report aims to make more accessible to community advocates discussions around ethical conduct of biomedical prevention trials in the era of PrEP. In early 2019, TAG, along with Black AIDS Institute and the HIV Vaccine Trials Network developed an…
Treatment Action Group acknowledges with profound disappointment today’s announcement that the HIV Vaccine Trials Network HVTN 702 study did not demonstrate efficacy in preventing HIV acquisition.